Abstract
[ImH][trans-RuIIICl4(DMSO)(Im)] (where DMSO is dimethyl sulfoxide and Im is imidazole) (NAMI-A) is an antimetastatic prodrug currently in phase II clinical trials. The mechanisms of action of this and related Ru-based anticancer agents are not well understood, but several cellular targets have been suggested. Although Ru has been observed to bind to DNA following in vitro NAMI-A exposure, little is known about Ru–DNA interactions in vivo and even less is known about how this or related metallodrugs might influence cellular RNA. In this study, Ru accumulation in cellular RNA was measured following treatment of Saccharomyces cerevisiae with NAMI-A. Drug-dependent growth and cell viability indicate relatively high tolerance, with approximately 40% cell death occurring at 6 h for 450 μM NAMI-A. Significant dose-dependent accumulation of Ru in cellular RNA was observed by inductively coupled plasma mass spectrometry measurements on RNA extracted from yeast treated with NAMI-A. In vitro, binding of Ru species to drug-treated model DNA and RNA oligonucleotides at pH 6.0 and 7.4 was characterized by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry in the presence and absence of the reductant ascorbate. The extent of Ru–nucleotide interactions increases slightly with lower pH and significantly in the presence of ascorbate, with differences in observed species distribution. Taken together, these studies demonstrate the accumulation of aquated and reduced derivatives of NAMI-A on RNA in vitro and in cellulo, and enhanced binding with nucleic acid targets in a tumorlike acidic, reducing environment. To our knowledge, this is also the first study to characterize NAMI-A treatment of S. cerevisiae, a genetically tractable model organism.
Similar content being viewed by others
Abbreviations
- cfu:
-
Colony-forming units
- DMSO:
-
Dimethy sulfoxide
- ICP-MS:
-
Inductively coupled plasma mass spectrometry
- Im:
-
Imidazole
- MALDI:
-
Matrix-assisted laser desorption/ionization
- OD600 :
-
Optical density at 600 nm
- NAMI:
-
[Na][trans-RuIIICl4(DMSO)(Im)]
- NAMI-A:
-
[ImH][trans-RuIIICl4(DMSO)(Im)]
- THAP:
-
2′,4′,6′-Trihydroxyacetophenone
- TOF:
-
Time-of-flight
- YEPD:
-
Yeast extract–peptone–glucose
References
Hannon MJ (2007) Pure Appl Chem 79:2243–2261
Dyson PJ, Sava G (2006) Dalton Trans 1929–1933
Rademaker-Lakhai JM, van den Bongard D, Pluim D, Beijnen JH, Schellens JHM (2004) Clin Cancer Res 10:3717–3727
Levina A, Mitra A, Lay PA (2009) Metallomics 1:458–470
Kostova I (2006) Curr Med Chem 13:1085–1107
Bergamo A, Gagliardi R, Scarcia V, Furlani A, Alessio E, Mestroni G, Sava G (1999) J Pharmacol Exp Ther 289:559–564
Sava G, Capozzi I, Bergamo A, Gagliardi R, Cocchietto M, Masiero L, Onisto M, Alessio E, Mestroni G, Garbisa S (1996) Int J Cancer 68:60–66
Sava G, Bergamo A, Zorzet S, Gava B, Casarsa C, Cocchietto M, Furlani A, Scarcia V, Serli B, Iengo E, Alessio E, Mestroni G (2002) Eur J Cancer 38:427–435
Ravera M, Baracco S, Cassino C, Zanello P, Osella D (2004) Dalton Trans 2347–2351
Gullino PM (1976) Adv Exp Biol Med 75:521–536
Richard DE, Berra E, Pouyssegur J (1999) Biochem Biophys Res Commun 266:718–722
Gerweck LE, Vijayappa S, Kozin S (2006) Mol Cancer Ther 5:1275–1279
Brabec V, Novakova O (2006) Drug Resist Update 9:111–122
Pizarro AM, Sadler PJ (2009) Biochimie 91:1198–1211
Pluim D, van Waardenburg RCAM, Beijnen JH, Schellens JHM (2004) Cancer Chemother Pharmacol 54:71–78
Gallori E, Vettori C, Alessio E, Vilchez FG, Vilaplana R, Orioli P, Casini A, Messori L (2000) Arch Biochem Biophys 376:156–162
Messori L, Casini A, Vullo D, Haroutiunian SG, Dalian EB, Orioli P (2000) Inorg Chim Acta 303:283–286
Jung Y, Lippard SJ (2007) Chem Rev 107:1387–1407
Bacac M, Hotze ACG, van der Schilden K, Haasnoot JG, Pacor S, Alessio E, Sava G, Reedijk J (2004) J Inorg Biochem 98:402–412
Schluga P, Hartinger CG, Egger A, Reisner E, Galanski M, Jakupec MA, Keppler BK (2006) Dalton Trans 1796–1802
Groessl M, Tsybin YO, Hartinger CG, Keppler BK, Dyson PJ (2010) J Biol Inorg Chem 15:677–688
Malina J, Novakova O, Keppler BK, Alessio E, Brabec V (2001) J Biol Inorg Chem 6:435–445
Mattick JS (2004) Nat Rev Genet 5:316–323
Kong QM, Lin CLG (2010) Cell Mol Life Sci 67:1817–1829
Olmo N, Turnay J, González de Buitrago G, López de Silanes I, Gavilanes JG, Lizarbe MA (2001) Eur J Biochem 268:2113–2123
Jetzt AE, Cheng JS, Tumer NE, Cohick WS (2009) Int J Biochem Cell B 41:2503–2510
Mroczek S, Kufel J (2008) Nucleic Acids Res 36:2874–2888
Mei Y, Yong J, Liu H, Shi Y, Meinkoth J, Dreyfuss G, Yang X (2010) Mol Cell 37:668–678
Akaboshi M, Kawai K, Maki H, Akuta K, Ujeno Y, Miyahara T (1992) Jpn J Cancer Res 83:522–526
Schmittgen TD, Ju J-F, Danenberg KD, Danenberg PV (2003) Int J Oncol 23:785–789
Heminger KA, Hartson SD, Rogers J, Matts RL (1997) Arch Biochem Biophys 344:200–207
Menacho-Marquez M, Murguia JR (2007) Clin Trans Oncol 9:221–228
McCarthy JEG (1998) Microbiol Mol Biol Rev 62:1492–1553
Phizicky EM, Hopper AK (2010) Genes Dev 24:1832–1860
Barr MM (2003) Physiol Genomics 13:15–24
Alessio E, Balducci G, Calligaris M, Costa G, Attia WM, Mestroni G (1991) Inorg Chem 30:609–618
Witkowsky L (2006) Senior thesis. Willamette University
Tyson CB, Lord PG, Wheals AE (1979) J Bacteriol 138:92–98
Chapman EG, DeRose VJ (2010) J Am Chem Soc 132:1946–1952
Ragas JA, Simmons TA, Limbach PA (2000) Analyst 125:575–581
Sauer S (2007) J Biochem Biophys Methods 70:311–318
Christian NP, Reilly JP, Mokler VR, Wincott FE, Ellington AD (2001) J Am Soc Mass Spectrom 12:744–753
National Institute of Standards and Technology (2010) Physical measurement laboratory: basic atomic spectroscopic data. http://physics.nist.gov/PhysRefData/Handbook/Tables/rutheniumtable1.htm. Accessed 5 Jan 2011
Ang WH, Daldini E, Scolaro C, Scopelliti R, Juillerat-Jeannerat L, Dyson PJ (2006) Inorg Chem 45:9006–9013
Bergamo A, Messori L, Piccoli F, Cocchietto M, Sava G (2003) Invest New Drugs 21:401–411
Warner JR (1999) Trends Biochem Sci 24:437–440
Hinnebusch AG (2009) Genes Dev 23:891–895
Horn HF, Vousden KH (2007) Oncogene 26:1306–1316
Brindell M, Stawoska I, Supel J, Skoczowski A, Stochel G, van Eldik R (2008) J Biol Inorg Chem 13:909–918
Brindell M, Piotrowska D, Shoukry AA, Stochel G, van Eldik R (2007) J Biol Inorg Chem 12:809–818
Calligaris M, Carugo O (1996) Coord Chem Rev 153:83–154
Acknowledgements
We thank Andy Ungerer for assistance with the ICP-MS experiments, the W. M. Keck Collaboratory for Plasma Spectrometry at Oregon State University, J. David Sumega for synthesizing and characterizing NAMI-A, and Laurie Graham for assistance with protocols and imaging. The Stevens laboratory at the University of Oregon is gratefully acknowledged for the use of a Carl Zeiss Axioplan 2 fluorescence microscope and for a gift of the BY4741 strain. This work was supported by a Willamette University Atkinson Grant (K.L.M.H.), the NIH (GM058096, V.J.D.), and the University of Oregon (V.J.D.).
Author information
Authors and Affiliations
Corresponding authors
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Hostetter, A.A., Miranda, M.L., DeRose, V.J. et al. Ru binding to RNA following treatment with the antimetastatic prodrug NAMI-A in Saccharomyces cerevisiae and in vitro. J Biol Inorg Chem 16, 1177–1185 (2011). https://doi.org/10.1007/s00775-011-0806-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00775-011-0806-7